drugset / Trial / NCT01257425

Equivalence of Intramuscular (IM) Versus Subcutaneous (SC) Applications of Long Acting Pamorelin 11.25 mg

NCT01257425

Phase 2 Completed 109 enrolled Ipsen
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to demonstrate the pharmacodynamic equivalence of triptorelin pamoate (Pamorelin® LA 11.25 mg), applied either IM or SC, in terms of the area under the curve \[AUC1-85day\] for serum testosterone in patients with advanced prostate cancer.

Timeline

Start
2010-12
Primary completion
2012-02
Completion
2012-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Triptorelin Other / unclassified 11.25 mg Intramuscular

Indications